The potential of statins as part of anti-cancer treatment

European Journal of Cancer

Volumn 41, Issue 4, 2005, Pages 516-522

  Sleijfer, Stefan ^a   Van Der Gaast, Ate ^a   Planting, André S Th ^a   Stoter, Gerrit ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti tumour activity; Drug combinations; Solid tumours; Statins

Indexed keywords

ACETYLSALICYLIC ACID; CARMUSTINE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; UBIQUINONE;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; DNA DAMAGE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENZYME INHIBITION; ETHNOLOGY; FEASIBILITY STUDY; GLIOMA; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL CARCINOMA; LIVER TOXICITY; MYOPATHY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STEADY STATE; TREATMENT WITHDRAWAL; TUMOR BIOPSY;

EID: 14344260532     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.009     Document Type: Review

References (42)

1. Editorial. OTC statins: a bad decision for public health. The Lancet 2004, 363, 1659
2. J. Wejde, M. Hjertman, and M. Carlberg Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation J Cell Biochem 71 1998 502 514
3. J.L. Bos Ras oncogenes in human cancer Cancer Res 49 1989 4682 4689
4. E.A. Collisson, C. Kleer, and M. Wu Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells Mol Cancer Ther 2 2003 941 948
5. J. Dimitroulakos, L.Y. Ye, and M. Benzaquen Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications Clin Cancer Res 7 2001 158 167
6. W. Feleszko, E.Z. Balkowiec, and E. Sieberth Lovastatin and tumor necrosis factor-α exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis Int J Cancer 81 1999 560 567
7. T. Kusama, M. Mukai, and T. Iwasaki Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors Cancer Res 61 2001 4885 4891
8. A. Wächterhäuser, B. Akoglu, and J. Stein HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2 Carcinogenesis 22 2001 1061 1067
9. 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase Proc Natl Acad Sci USA 96 1999 7797 7802
10. W.S. Kim, M.M. Kim, and H.J. Choi Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma Invest New Drugs 19 2001 81 83
11. 1 cyclin-dependent kinases J Biol Chem 278 2003 43586 43594
12. S.J. Lee, M.J. Ha, and J. Lee Inhibition of the 3-hydroxy-3- methylglutaryl-coenzume A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells J Biol Chem 273 1998 10618 10623
13. R. Gniadecki Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis Biochem Biophys Res Commun 320 2004 165 169
14. M. Werner, J. Sacher, and M. Hohenegger Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells Br J Pharmacol 143 2004 715 724
15. M. Frick, J. Dulak, and J. Cisowski Statins differentially regulate vascular endothelial growth factor in endothelial and vascular smooth muscle cells Atherosclerosis 170 2003 229 236
16. 1 cell cycle arrest Anti-Cancer Drugs 15 2004 625 632
17. T. Kusama, M. Mukai, and T. Iwasaki 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis Gastroenterology 122 2002 308 317
18. T. Nubel, W. Dippold, and H. Kleinert Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion FASEB J 18 2004 140 142
19. J. Silva, A. Beckedorf, and E. Bieberich Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells J Biol Chem 278 2003 25376 25385
20. B.-W. Yang, Y.-S. Wang, and S.-J. Lin Ras signaling is involved in the expression of Fas-L in glioma Lab Invest 80 2000 529 537
21. J. Shepherd, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial The Lancet 360 2002 1623 1630
22. L.M. Bjerre, and J. LeLorier Do statins cause cancer? A meta-analysis of large randomized trials Am J Med 110 2001 716 723
23. P.F. Coogan, L. Rosenberg, and J.R. Palmer Statin use and the risk of breast and prostate cancer Epidemiology 13 2002 262 267
24. J.A. Kaye, C.R. Meier, and A.M. Walker Statin use, hyperlipidaemia, and the risk of breast cancer Br J Cancer 86 2002 1436 1439
25. D.M. Boudreau, J.S. Gardner, and K.E. Malone The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study Cancer 100 2004 2308 2316
26. M.R. Graaf, A.B. Beiderbeck, and A.C.G. Egberts The risk of cancer in users of statins J Clin Oncol 22 2004 2388 2394
27. J.N. Poynter HMG-CoA reductase inhibitors and the risk of colorectal cancer Proc ASCO 22 14S 2004 1
28. L. Blais, A. Desgagné, and J. LeLorier 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer Arch Intern Med 160 2000 2363 2368
29. A. Thibault, D. Samid, and A.C. Tompkins Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res 2 1996 483 491
30. J. Larner, J. Jane, and E. Klaws A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme Am J Clin Oncol 21 1998 579 583
31. Knox JJ, Siu LL, Chen E, et al. A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer, (this issue)
32. K.K.W. Chan, A.M. Oza, and L.L. Siu The statins as anticancer drugs Clin Cancer Res 9 2003 10 19
33. S. Kawata, E. Yamasaki, and T. Nagase Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial Br J Cancer 84 2001 886 891
34. A.J. Mantha, K.E. McFee, and N. Niknejad Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells J Cancer Res Clin Oncol 129 2003 631 641
35. M.R. Soma, R. Baetta, and M.R. De Renzis In vivo enhanced antitumor activity of carmustine [N,N′-bis (2-chloroethyl)-N-nitrosourea] by simvastatin Cancer Res 55 1995 597 602
36. W. Wang, E. Collie-Duguid, and J. Cassidy Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines FEBS Lett 531 2002 415 420
37. B. Agarwal, S. Bhendwal, and B. Halmos Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells Clin Cancer Res 5 1999 2223 2229
38. W. Feleszko, I. Mlynarczuk, and E.Z. Balkowiec-Iskra Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice Clin Cancer Res 6 2000 2044 2052
39. W. Feleszko, I. Mlynarczuk, and D. Olszewska Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apopotosis-dependent mechanism Int J Cancer 100 2002 111 118
40. C. Muller-Tidow, M. Kiehl, and J.R. Sindermann Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells Int J Oncol 23 2003 151 158
41. A.C. Miller, K. Kariko, and C.E. Myers Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation Int J Cancer 53 1993 302 307
42. M.S. Katz, B.D. Minsky, and L.B. Saltz Statin use may increase the pathological complete response rate after neoadjuvant chemoradiation for rectal cancer Proc Am Soc Clin Oncol 2004 [abstract 3568]